Annual General Meeting

RNS Number : 8662K

Oxford Biomedica PLC

27 April 2010

 



FOR IMMEDIATE RELEASE

27 April 2010

OXFORD BIOMEDICA PLC

ANNUAL GENERAL MEETING

Oxford, UK - 27 April 2010: Oxford BioMedica (LSE: OXB), a leading gene therapy company, announced today that all resolutions proposed were duly passed at its Annual General Meeting (AGM), held today in London.

Resolution 12 (to empower the Directors to issue of up to 10% of current issued shares without reference to the pre-emption rights specified in the Companies Act 2006) was withdrawn prior to the AGM. The Directors took account of the proxy votes cast prior to the meeting, and intend to consult further with shareholders and to reconsider this at the 2011 AGM. 

In accordance with Listing Rule 9.6.18, the following resolutions are those which were passed at the meeting concerning special business:

·     Resolution 10: to empower the Directors to allot equity securities, pursuant to section 551 of the Companies Act 2006 (the "Act"), up to an aggregate nominal amount of £1,810,197 with a further aggregate nominal amount of £1,810,197 authorised in connection with a rights issue, or where applicable, other proportionate offer;

·     Resolution 11: to empower the Directors to allot equity securities for cash, pursuant to section 570 of the Act as if section 561 of the Act did not apply to such allotment, up to an aggregate nominal amount representing 5 per cent of presently issued shares;

·     Resolution 13: to delete the provisions of the Company's former Memorandum and to adopt New Articles of Association, to implement changes brought in by Act; and

·     Resolution 14: to permit the Company to convene general meetings (other than annual general meetings) by not less than 14 days notice.

The full text of all the resolutions can be viewed in the Notice of Meeting by visiting our website at www.oxfordbiomedica.co.uk

Certified copies of the document setting out the above resolutions passed at the 2010 AGM have been submitted to the UK Listing Authority and will shortly be made available for inspection at the UK Listing Authority's Document Viewing Facility, which is situated at The Financial Services Authority, 25 The North Colonnade, Canary Wharf, London, E14 5HS.

The results of the proxy voting in advance of the meeting shown below. On the Record Date (25 April 2010) there were 543,059,034 1p ordinary shares in issue, each carrying one vote per share.

Resolution	Votes  For	Votes at  Chairman's Discretion	Votes at  other proxy Discretion	Votes Against	Votes  Withheld	Total votes cast	Result
Ordinary resolutions (1-10)
1	165,790,753	238,045	546,522	42,485	626,976	166,617,805	Passed
2	88,357,708	257,173	546,522	77,315,101	768,277	166,476,504	Passed
3	165,415,380	254,584	546,522	284,268	744,027	166,500,754	Passed
4	165,523,398	254,584	546,522	174,688	745,589	166,499,192	Passed
5	165,436,616	254,584	546,522	260,803	746,256	166,498,525	Passed
6	164,747,244	254,584	546,522	175,313	1,521,118	165,723,663	Passed
7	165,510,750	254,584	546,522	187,336	745,589	166,499,192	Passed
8	165,536,287	265,399	546,522	152,546	744,027	166,500,754	Passed
9	165,758,952	245,034	546,522	67,027	627,246	166,617,535	Passed
10	164,243,469	264,897	546,522	135,606	2,054,287	165,190,494	Passed
Special resolutions (11-14)
11	165,463,182	267,316	546,522	253,448	714,313	166,530,468	Passed
12	95,941,431	256,396	546,522	69,773,656	726,776	166,518,005	Withdrawn
13	165,617,351	279,841	546,522	126,209	674,858	166,569,923	Passed
14	163,396,762	263,382	546,522	2,395,193	642,922	166,601,859	Passed

-Ends-

For further information, please contact:
Oxford BioMedica plc: John Dawson, Chief Executive Officer	Tel: [phone]
JPMorgan Cazenove Limited: James Mitford/ Gina Gibson	Tel: [phone]
City/Financial Enquiries: Lisa Baderoon/ Mark Court  Buchanan Communications	Tel: [phone]
US Enquiries: Thomas Fechtner The Trout Group LLC	Tel: [phone]

Notes to editors

1. Oxford BioMedica

Oxford BioMedica (LSE: OXB) is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient gene delivery system (LentiVector^®), which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline and its partners include sanofi-aventis, Sigma-Aldrich and Pfizer. Technology licensees include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Further information is available at www.oxfordbiomedica.co.uk

 

END

 

 

RAGKKODQDBKDQQB